Randomized trial of three induction antibodies in kidney transplantation: Long-Term results

Transplantation

Volumn 97, Issue 11, 2014, Pages 1128-1138

  Ciancio, Gaetano ^a   Gaynor, Jeffrey J ^a   Guerra, Giselle ^a   Sageshima, Junichiro ^a   Chen, Linda ^a   Mattiazzi, Adela ^a   Roth, David ^a   Kupin, Warren ^a   Tueros, Lissett ^a   Flores, Sandra ^a   Hanson, Lois ^a   Vianna, Rodrigo ^a   Burke, George W ^a  

^a Florida   (United States)

Author keywords

Alemtuzumab; Antithymocyte globulin; Biopsy proven acute rejection; Biopsy proven chronic allograft injury; Campath 1H; Daclizumab; Death censored graft survival; Long Term follow up.

Indexed keywords

ALEMTUZUMAB; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ABSCESS; ACUTE GRAFT REJECTION; ADULT; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BRONCHITIS; CELLULITIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; GRAFT SURVIVAL; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNOREGULATION; INFECTION; INFLUENZA; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOPENIA; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PNEUMONIA; POLYOMAVIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SEPSIS; SINUSITIS; TREATMENT RESPONSE; URINARY TRACT INFECTION; VIRUS INFECTION;

ADRENAL CORTEX HORMONES; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; CADAVER; CREATININE; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TACROLIMUS; TREATMENT OUTCOME;

EID: 84902157549     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000441089.39840.66     Document Type: Article

References (60)

1. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161.
2. Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999; 67: 110.
3. Ciancio G, Burke GW, Suzart K, et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002; 73: 1100.
4. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes following renal transplant. Transplantation 1998; 66: 29.
5. Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003; 76: 798.
6. Matas AJ, Kandaswamy R, Humar A, et al. Long-Term immunosuppression, without maintenance prednisone, after kidney transplantation. Ann Surg 2004; 240: 510.
7. Knechtle SJ, Pirsch JD, Fechner JH Jr, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722.
8. Ciancio G, Burke GW, Gaynor JJ, et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004; 78: 426.
9. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701.
10. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immunemonitoring. Transplantation 2005; 80: 457.
11. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized trial of thymoglobulin vs. Alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow up. Clin Transplant 2008; 22: 200.
12. Ciancio G, Gaynor JJ, Roth D, et al. Randomized trial of thymoglobulin vs. Alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in living donor renal transplantation. Transplant Proc 2010; 42: 3503.
13. Heilman RL, Younan K, Wadei HM, et al. Results of a prospective randomized trial of sirolimus conversion in kidney transplant recipients on early corticosteroid withdrawal. Transplantation 2011; 92: 767.
14. Heilman RL, Cortese C, Geiger XJ, et al. Impact of early conversion from tacrolimus to sirolimus on chronic allograft changes in kidney recipients on rapid steroid withdrawal. Transplantation 2012; 93: 47.
15. DellOglio MP, Zaza G, Rossini M, et al. The anti-fibrotic effect of mycophenolic acid-induced neutral endopeptidase. J Am Soc Nephrol 2010; 21: 2157.
16. Vincenti F, Monaco A, Grinyo J, et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306.
17. Kumar MSA, Xiao SG, Fyfe B, et al. Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies. Clin Transplant 2005; 19: 61.
18. Laftavi MR, Stephan R, Stefanick B, et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005; 137: 364.
19. Nematalla AH, Bakr MA, Gheith OA, et al. Steroid-Avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study. Exp Clin Transplant 2007; 2: 673.
20. Woodle ES, First MR, Pirsch J, et al. for the Astellas Corticosteroid Withdrawal Study Group. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (day 7) corticosteroid cessation versus long-Term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564.
21. Vincenti F, Schena FP, Parakevas S, et al. on behalf of the FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307.
22. MontagninoG, Sandrini S, Iorio B, et al. A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine. Nephrol Dial Transplant 2008; 23: 707.
23. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H). Transplantation 2003; 76: 120.
24. Kirk AD, Mannon RB, Kleiner DE, et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005; 80: 1051.
25. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005; 5: 465.
26. Vathsala A, Ona ET, Tan SY, et al. Randomized trial of alemtuzumab for prevention of graft rejection and preservation of renal function after kidney transplantation. Transplantation 2005; 80: 765.
27. Thomas PG, Woodside KJ, Lappin JA, et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. Transplantation 2007; 83: 1509.
28. Margreiter R, Klempnauer J, Neuhaus P, et al. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am J Transplant 2008; 8: 1480.
29. Farney AC, Doares W, Rogers J, et al. A randomized trial of alemtuzumab vs. Antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 2009; 88: 810.
30. Hanaway MJ, Woodle ES, Mulgaonkar S, et al. for the INTAC Study Group. Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909.
31. Chan K, Taube D, Roufosse C, et al. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapyVan open label, randomized trial. Transplantation 2011; 92: 774.
32. Cherukuri A, Salama AD, Carter C, et al. An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation. AmJ Transplant 2012; 12: 919.
33. Morgan RD, OCallaghan JM, Knight SR, et al. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-Analysis. Transplantation 2012; 93: 1179.
34. Huang E, Cho YW, Hayashi R, et al. Alemtuzumab induction in deceased donor kidney transplantation. Transplantation 2007; 84: 821.
35. SampaioMS, Kadiyala A, Gill J, et al. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation. Transplantation 2009; 88: 904.
36. Knechtle SJ, Fernandez LA, Pirsch JD, et al. Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 2004; 136: 754.
37. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab inductionVlong-Term results. Am J Transplant 2005; 5: 2539.
38. Shapiro R, Basu A, Tan H, et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with thymoglobulin or campath. J Am Coll Surg 2005; 200: 505.
39. Watson CJE, Bradley JA, Friend PJ, et al. Alemtuzumab (Campath-1H) induction therapy in cadaveric kidney transplantationVefficacy and safety at five years. Am J Transplant 2005; 5: 1347.
40. Ortiz J, Palma-Vargas J, Wright F, et al. Campath induction for kidney transplantation: report of 297 cases. Transplantation 2008; 85: 1550.
41. Tan HP, Donaldson J, Basu A, et al. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant 2009; 9: 355.
42. Knechtle SJ, Pirsch JD, Fechner JH Jr, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722.
43. Cai J, Terasaki PI, Bloom DD, et al. Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation 2004; 78: 919.
44. Flechner SM, Friend PJ, Brockmann J, et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005; 5: 3009.
45. Barth RN, Janus CA, Lillesand CA, et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression after renal transplantation. Transplant Int 2006; 19: 885.
46. Djamali A, Leverson G, Singh N, et al. Antibody-mediated rejection (AMR) in renal allograft recipients treated with alemtuzumab induction. Am J Transplant 2008; 8(suppl 2): 237 (Abstract #222).
47. Knechtle SJ, Pascual J, Bloom DD, et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant 2009; 9: 1087.
48. Willicombe M, Roufosse C, Brookes P, et al. Antibody-mediated rejection after alemtuzumab induction: incidence, risk factors, and predictors of poor outcome. Transplantation 2011; 92: 176.
49. LaMattina JC, Mezrich JD, Hofmann RM, et al. Alemtuzumab as compared to alternative contemporary induction regimens. Transplant Int 2012; 25: 518.
50. Bloom DD, Chang Z, Fechner JH, et al. CD4+CD25+FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008; 8: 793.
51. Macedo C, Walters JT, Orkis EA, et al. Long-Term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. Transplantation 2012; 93: 813.
52. Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48.
53. Mourad G, Rastaing L, Legendre C, et al. Sequential protocols using basiliximab versus anti-Thymocyte globulins in renal-Transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004; 78: 584.
54. Kandus A, Arnol M, Omahen K, et al. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. Transplantation 2010; 89: 1022.
55. Brennan DC, Daller JA, Lake KD, et al. for the Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967.
56. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-Term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I Drug interactions and rejection at one year. Transplantation 2004; 77: 244.
57. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-Term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77: 252.
58. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44: 411.
59. Solez K, Colvin RB, Racusen LC, et al. Banff 05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (CAN). Am J Transplant 2007; 7: 518.
60. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.